Contract researcher Quintiles speeds up operation in Taiwan
By Kathryn Chiu, The China Post
August 1, 2014, 12:45 am TWN
TAIPEI, Taiwan -- Quintiles Taiwan (昆泰公司) has managed an average of 25 clinical trial approvals from local regulators over the past five years, which is an annual growth of 28.7 percent, placing it second only to mainland China among all other Asian markets.
Quintiles is the world's largest contract research organization as well as the world's largest provider of biopharma development services and commercial outsourcing services.
Quintiles Taiwan registered its office and began operations in 1998 and had 35 staff in 2007 just before moving into its office at the Cathay Life Cosmos Building. The firm currently has more than 150 employees with annual staff retention near 90 percent.
Quintiles Taiwan said it has conducted around 170 clinical research studies involving close to 5,589 patients, adding that it has more than 30 active projects.
According to Quintiles Taiwan, it has for the past five years managed an average of 25 trial approvals by the Food and Drug Administration (FDA, 食品藥物管理署) each year.
Quintiles is a Fortune 500 company and was named on Computerworld's “100 Best Places to Work in IT” list for the sixth time in seven years.
Quintiles Taiwan said that oncology drug development is by far its No. 1 area of work, followed by infectious disease and clinical nurse specialization in the fields of psychiatry and neurology. Quintiles' services in Taiwan include clinical project management, trial monitoring, quality assurance/quality control, regulatory affairs, feasibility services and site start-up as well as learning and development.
Quintiles indicated most of its work in Taiwan is in phase 3 trials; with increasing focus on phase 1 and phase 2 trials, followed by late-phase work.